Symbicort NDA On-Track Despite FDA Data Request, AstraZeneca Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has requested additional chemistry, manufacturing and control data for Symbicort inhalation delivery device. While AstraZeneca does not believe this will significantly delay product development, the company does have a back-up strategy for a slightly modified device.
You may also be interested in...
AstraZeneca Files NDA For Symbicort Asthma Therapy
Company has discussed potential delays in review of the metered dose inhaler asthma product.
AstraZeneca Files NDA For Symbicort Asthma Therapy
Company has discussed potential delays in review of the metered dose inhaler asthma product.
GSK To Tout Positive Advair Study As Defense Against AstraZeneca Symbicort
New head-to-head study will provide "the ammunition to continue to…build the Advair franchise" in the U.S., GSK's Stout says. Since AstraZeneca's Symbicort is not approved in the U.S., the most immediate impact of the CONCEPT trial may be to help regain market share in the international market.